LTR PHARMA LIMITED — Director's Dealing 2025

Nov 19, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity LTR Pharma Limited ABN 42 103 087 449

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Julian Chick
Date of last notice	9 December 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.		Not applicable
Date of change		19 November 2025
No. of securities held prior to change		Direct808,492 Fully Paid Ordinary Shares500,000 Unlisted Options exercisable at $0.22per option expiring 31 October 2028100,000 Unlisted Options exercisable at $2.52per option expiring 2 December 2028Indirect46,373,750 Fully Paid Ordinary Shares held byLTR Medical Pty Ltd
Class		Unlisted Options
Number acquired		1,000,000

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Not applicable
Value/Consideration	Nil consideration
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change	Direct
	808,492 Fully Paid Ordinary Shares
	500,000 Unlisted Options exercisable at $0.22
	per option expiring 31 October 2028
	100,000 Unlisted Options exercisable at $2.52
	per option expiring 2 December 2028
	1,000,000 Unlisted Options exercisable at
	$0.5075 per option expiring 24 October 2029
	Indirect
	46,373,750 Fully Paid Ordinary Shares held by
	LTR Medical Pty Ltd
Nature of change	Issue of 1,000,000 Unlisted Options under the
Example: on-market trade, off-market trade, exercise of options, issue	Employee Incentive Plan as approved by
of securities under dividend reinvestment plan, participation in buy-back	shareholders at the Company’s 2025 Annual
	General Meeting (Resolution 8)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder	Not applicable
(if issued securities)
Date of change	Not applicable
No. and class of securities to which interest	Not applicable
related prior to change
Note: Details are only required for a contract in relation to which the
interest has changed
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration	Not applicable
Note: If consideration is non-cash, provide details and an estimated
valuation

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change Not applicable

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow thetrade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date wasthis provided?	Not applicable

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3